Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00322803
Status:
TERMINATED
Last Update Posted:
2006-09-29
First Post:
2006-05-05
Brief Title:
ELB139 Given Orally to Patients With Concurrent Panic Disorder Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment
Sponsor:
elbion AG
Organization:
elbion AG
Study Overview
Official Title:
International Multicenter Randomized Double-Blind Placebo Controlled Two-Period Cross-Over Study to Demonstrate Safety Tolerability and Anxiolytic Effects of 600 mg ELB139 Given Orally tid to Patients With Concurrent Panic Disorder Challenged by Inhalation of 35 CO2 After a Single Dose and One Week of Treatment
Status:
TERMINATED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to investigate if 600 mg ELB139 given orally tid to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35 CO2 measured by a visual analogue scale after the first intake and after approximately one week of treatment as compared to placebo treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT Number2005-005708-17 | None | None | None |